Article
Frequent Aneuploidy in Primary Human T Cells Following CRISPR-Cas9 cleavage
2021-08-20
Abstract excerpt
<h4>SUMMARY</h4> Multiple ongoing clinical trials use site-specific nucleases to disrupt T cell receptor (TCR) genes in order to allow for allogeneic T cell therapy 1–5 . In particular, the first U.S. clinical trial using CRISPR-Cas9 entailed the targeted disruption of the TCR chains and programmed cell death protein 1 (PDCD1) in T cells of refractory cancer patients 6 . Here, we used the same guide RNA sequenc...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d029b80b-49bf-5d7d-9130-7f5407fd7c5a
- DOI
- 10.1101/2021.08.20.457092
